FDA 510(k)

MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL

Número K: K211672 · 2021-10-20

Data da decisão2021-10-20

Código do produtoJWY

Comité consultivoMI

DecisãoSubstantially Equivalent

Resumo do dispositivo

MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL is the device name listed in this FDA 510(k) record. The listed applicant is Liofilchem s.r.l.. It received FDA 510(k) clearance on 2021-10-20 under 510(k) number K211672. The device is classified under product code JWY. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Perguntas frequentes

What is the MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL?

MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL is a medical device that received FDA 510(k) clearance on 2021-10-20. The listed applicant is Liofilchem s.r.l.. The 510(k) number is K211672.

When did MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL receive FDA 510(k) clearance?

MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL received FDA 510(k) clearance on 2021-10-20, under 510(k) number K211672.

Who is the listed applicant for MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL?

The FDA 510(k) record lists Liofilchem s.r.l. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL?

The FDA product code for MTS Piperacillin-tazobactam 0.016/4 - 256/4µg/mL is JWY.

Ensaios clínicos relacionados

Registros relacionados são pareados automaticamente usando nomes, códigos de produtos ou outros metadados. Um pareamento não estabelece um vínculo clínico, científico, corporativo ou regulatório verificado; revise as fontes oficiais vinculadas.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITING NCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITING NCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED NCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Outros registros que listam Liofilchem s.r.l. como candidato(a)

K260696MTS Gepotidacin 0.016-256 µg/mL K252114MTS Aztreonam-Avibactam 0.016/4 - 256/4 µg/mL K251580MTS Sulbactam-Durlobactam 0.004/4 - 64/4 µg/mL (SUD)K243202MTS Ceftobiprole 0.002-32 µg/mL K230479ComASP Cefiderocol 0.008-128 K200180MTS Omadacycline 0.002 - 32 ug/mL

Ver todos os 35 dispositivos →

Dispositivos Relacionados (Código: JWY)

K260447ETEST Gepotidacin (GEP) (0.016-256 µg/mL)bioMérieux SA K260696MTS Gepotidacin 0.016-256 µg/mLLiofilchem s.r.l.K252114MTS Aztreonam-Avibactam 0.016/4 - 256/4 µg/mLLiofilchem s.r.l.K252062O sistema Sensititre 18-24 hora MIC ou Suscetibilidade de Ponto com Colistina na faixa de diluição de 0,12-16 µg/mLThermo Fisher Scientific K250575The Sensititre 18 - 24 hour MIC or Breakpoint Susceptibility System with Aztreonam/avibactam in the dilution range of 0.008/4 - 64/4 ug/mLThermo Fisher Scientific K252014The Sensititre 18-24 hour MIC or Breakpoint Susceptibility System with Amikacin in the dilution range of 0.25-256 ug/mLThermo Fisher Scientific

Fonte oficial

Ver na base de dados da FDA →

Dados provenientes da FDA Open API. Para informações mais recentes e oficiais, consulte sempre o registro oficial.